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Abstract 
Background: High quality studies have been challenging to undertake in patients with metastatic epidural spinal 
cord compression. Nonetheless, in the article “Survival and Clinical Outcomes in Surgically Treated Patients With Meta-
static Epidural Spinal Cord Compression: Results of the Prospective Multicenter AOSpine Study” recently published in 
the Journal of Clinical Oncology, our team provided convincing evidence that spinal surgery improves overall quality 
of life in patients with this potentially devastating complication of cancer. Considering that metastatic spinal lesions 
treated with surgery have the highest mean cost among all oncological musculo-skeletal issues, it is essential to pro-
vide high quality data to optimize the therapeutic approaches and cost-effective use of health care resources.
Main body: Although the AOSpine Study provided high quality prospective data, it was primarily limited by the lack 
of non-operative controls and the relatively small sample size. Given the dearth of medical equipoise and the funda-
mental difference between patients deemed to be adequate surgical candidates and those who are not amenable to 
operative intervention, conducting a randomized controlled trial in this patient population was not felt to be ethi-
cally or medically feasible. Consequently, the optimal option to overcome limitations of both the lack of controls and 
the relatively small sample size is through collection of large prospective datasets through rigorously developed and 
maintained registries.
Conclusions: With the alarming increase in the incidence of cancer in China and China’s parallel growing cancer con-
trol efforts, China would offer a fantastic platform to set up a national metastatic spinal lesion registry. Such registry 
would not only enhance metastatic epidural spinal cord compression translational research but also optimize patient 
care.
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Background
This commentary is particularly timely since February 
4th marks each year the World Cancer Day, which pro-
motes global education, detection, and treatment of can-
cer through hundreds of events and activities organized 
worldwide.
In today’s scientific and medical climate, regardless 
of the field, progress faces two main areas of challenge: 
technical and economical, which often intertwine and 
influence each other. Although historically a diagnosis of 
metastatic epidural spinal cord compression (MESCC) 
was almost equivalent to a rapidly impending death sen-
tence, clinicians endeavoured to optimize the quality of 
life of these patients. Surgery, in the form of laminec-
tomy, followed by radiotherapy was a prevalent treatment 
option until the early 1980s [1] when a few retrospec-
tive studies [2–4] and one small randomized clinical trial 
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(RCT) [5] reported that radiotherapy alone was effective 
in alleviating pain and improving both ambulation and 
autonomic dysfunction. In addition, a prospective study 
stated that over 50% of MESCC patients developed evi-
dence of vertebral collapse and over 75% suffered a major 
neurological deterioration after laminectomy [6]. Con-
sequently, medical therapy in terms of corticosteroids 
and external beam radiotherapy became the therapeutic 
mainstay for metastatic spinal lesions [2–4]. Oncolo-
gists thus retained a primary role in the care of MESCC 
patients while the involvement of surgeons subsided 
significantly.
However, a better understanding of the principles of 
spinal stability and advances in spinal surgical techniques 
and internal fixation devices allowed the “rebirth” of sur-
gery as an adjunct to conventional medical treatments. In 
2005, Patchell et al. [7] conducted a milestone RCT which 
demonstrated that de novo circumferential decompres-
sive and reconstructive surgery followed by radiotherapy 
was superior in improving neurological outcomes than 
radiotherapy alone. In the United States, the number 
of MESCC patients who underwent surgical treatment 
increased by nearly 60% in 2009 compared to 2000 [8]. 
More specifically, Kelly et  al. [9]. reported that the rate 
of spinal surgery rose from an average of 3.8% to 4.9% 
per metastatic admission per year after the publication 
of Pathell’s RCT. Considering that of all skeletal-related 
events occurring in cancer patients, MESCC treated with 
surgery is currently associated with the highest mean 
costs [10, 11], evaluating the survival and clinical out-
comes in MESCC patients who undergo surgical treat-
ment is a topic of great interest not only for humanistic 
and clinical reasons but also for socio-economic reasons.
Main text
In our recent manuscript published in Journal of Clini-
cal Oncology, we reported the results of the AOSpine 
North America MESCC study, a prospective, multicenter, 
observational, cohort study conducted over a 5-year 
period in ten North American sites for which a total of 
142 surgically treated patients with a single symptomatic 
MESCC lesion were followed postoperatively for at least 
12  months [12]. The goal was to evaluate the impact of 
surgery on both clinician-assessed criteria and patient-
reported functional and health-related quality of life 
(HRQoL) outcomes using validated instruments, such as 
the International Standards For Neurologic Classification 
of Spinal Cord Injury (ISNCSCI), Short Form 36 Health 
Survey version 2 (SF-36 v2), and EuroQol 5 dimensions 
(EQ-5D). Although this study provided high quality 
data given its prospective design and rigorous externally 
monitored data collection and coding, it was primarily 
limited by its lack of controls and the small sample size. 
The lack of controls is a difficult issue to address. Due 
to serious ethical concerns, conducting a study in which 
patients suffering from a symptomatic MESCC lesion 
and deemed adequate surgical candidates would be ran-
domly assigned to either a surgical or a non-surgical 
treatment arm seems virtually impossible. Moreover, 
MESCC patients considered adequate surgical candi-
dates are fundamentally different from those who are not 
considered able to tolerate a spinal operative procedure; 
comparing these two sub-populations would represent a 
major threat to internal validity. In this context, the opti-
mal option to overcome limitations of both the lack of 
controls and small sample size is through using a registry.
Cancer mortalities have been increasing in China for 
the past 30  years and cancer is now the second lead-
ing cause of death [13, 14]. The Agency for Research 
on Cancer (IARC), the specialized cancer agency of the 
World Health Organization (WHO), reported that Chi-
nese patients accounted for 21.8% of the total number of 
newly diagnosed cancer patients in the world, with over 
3.06 million of new cases, and 26.9% of cancer death 
across the globe, with 2.2 million of cancer death cases, 
in 2012 [15]. Considering that approximately 10% of can-
cer patients will develop symptomatic spinal metastasis, 
50% of which will require treatment, and 5% to 10% of 
which will involve spinal surgery [16], we could estimate 
that of those 3.06 million of people diagnosed with can-
cer, 306,000 developed symptomatic spinal metastasis, 
153,000 needed treatment, and up to over 30,000 under-
went spinal surgery. Therefore, over two per 100,000 peo-
ple of the overall Chinese population may have required 
spinal surgery for a MESCC lesion in 2012. Given that 
lung cancer is the most common cancer in China [13, 
14] and accounts for about 20% of MESCC [17, 18], this 
could likely underestimate the magnitude of spinal sur-
geries performed for MESCC in China today. Conse-
quently, with China’s growing effort in fighting not only 
lung cancer [19] but cancer at large, China would offer a 
fantastic platform to set up a national MESCC registry.
Data completeness is the most important factor in 
achieving a high quality registry. Having a designated 
individual in every cancer institution responsible for 
thoroughly collecting patient demographics and clinical 
information as soon as a patient is diagnosed with spinal 
metastasis would provide data of the utmost value to per-
form epidemiologic, clinical, and economic analyses. To 
date, patient’s life expectancy has been given the greatest 
weight in orienting clinical decision-making processes 
for MESCC patients. However, maintenance or enhance-
ment of quality of life is also a crucial aspect to consider 
in this patient population.
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Conclusions
The AOSpine MESCC study provided high quality data 
suggesting that the majority of MESCC patients suffering 
from a single symptomatic lesion would have their overall 
HRQoL improved postoperatively. To build on this work, 
we would strongly advocate for the development of high 
quality prospective registries for metastatic spinal cancer. 
Such registries, including those undertaken by the Global 
Spine Tumor Study Group (GSTSG) [20] and the AOS-
pine Knowledge Forum-Oncology [21], would include 
questions such as: what are the modifiable and non-
modifiable preoperative predictive factors of survival, 
neurological, functional, and HRQoL outcomes, and of 
complications in surgical MESCC patients or which out-
come measure(s) are best suited for these patients.
Such registries would enhance not only MESCC 
research but also patient care. MESCC patients would be 
systematically identified as soon as they are referred to 
an oncologist and could therefore be put under the care 
of a multidisciplinary team consisting of medical and 
radiation oncologists, radiologists, and spinal surgeons as 
part of a standardized protocol management for MESCC 
patients. This would, for instance, prevent patients with 
symptomatic MESCC lesions being referred too late to 
a spinal surgeon and thus would maximize HRQoL out-
comes after treatment.
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